Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLEY WILSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1932398757
CMS profile
224261
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$389.28

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $389.28 8

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLEY WILSON

NPI 1932398757 · CMS profile ID 224261

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1932398757?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $389.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $20.3411/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938955291 CMS
IDORSIA PHARMACEUTICALS US INC $125.0011/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951474987 CMS
Janssen Biotech, Inc. $23.2610/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885758267 CMS
Corium, LLC $122.4009/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924876759 CMS
Janssen Biotech, Inc. $17.9409/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885758261 CMS
Journey Medical Corporation $15.8208/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924778721 CMS
Lilly USA, LLC $28.5507/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918158195 CMS
Regeneron Healthcare Solutions, Inc. $35.9706/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927483773 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,773.33 11
PY2020 $65.09 3
PY2021 $268.69 10
PY2022 $389.28 8
PY2023 $1,820.04 73
PY2024 $683.61 29
PY2025 $717.46 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,698,890.20 111
PY2024 Principal investigator $3,248,583.50 103
PY2023 Recipient $1,039.86 1
PY2023 Principal investigator $1,084,081.62 189
PY2022 Recipient $1,428.00 1
PY2022 Principal investigator $532,395.28 190
PY2021 Recipient $1,678.03 1
PY2021 Principal investigator $1,711,588.07 233
PY2020 Principal investigator $1,081,919.61 115
PY2019 Principal investigator $698,002.09 160

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

234 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $654.00 12/31/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012055
Principal investigator 1 ABBVIE INC. $75.00 12/30/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792488725
Principal investigator 1 ABBVIE INC. $42.18 12/30/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792488727
Principal investigator 1 ABBVIE INC. $109.19 12/30/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792488729
Principal investigator 1 PFIZER INC. $1,856.25 12/29/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832555359
Principal investigator 1 Incyte Corporation $10,824.47 12/28/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145921
Principal investigator 1 Incyte Corporation $9,238.05 12/28/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145923
Principal investigator 1 Incyte Corporation $10,606.28 12/28/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145925
Principal investigator 1 Incyte Corporation $18,335.24 12/28/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145927
Principal investigator 1 Incyte Corporation $1,218.00 12/17/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145917
Principal investigator 1 Incyte Corporation $350.00 12/17/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145919
Principal investigator 1 ABBVIE INC. $585.42 12/16/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792487359
Principal investigator 1 ABBVIE INC. $2,100.00 12/16/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792487361
Principal investigator 1 Eli Lilly and Company $12.02 12/16/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819449861
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $520.00 12/15/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 851031381
Principal investigator 1 Allergan, Inc. $2,096.10 12/14/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012053
Principal investigator 1 Incyte Corporation $1,298.70 12/13/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145915
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,050.00 12/03/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 851030961
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $2,500.00 12/03/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 851030967
Principal investigator 1 Allergan, Inc. $4,812.00 12/01/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012051
Principal investigator 1 Incyte Corporation $7,176.60 12/01/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145909
Principal investigator 1 Incyte Corporation $22,033.56 12/01/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145911
Principal investigator 1 Incyte Corporation $3,267.71 12/01/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145913
Principal investigator 1 ABBVIE INC. $545.77 11/23/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792484035
Principal investigator 1 ABBVIE INC. $3,675.00 11/23/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792484037
Principal investigator 1 GW Research Limited $15,346.65 11/23/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
GWAP19030 No dispute reported 06/30/2026 841422435
Principal investigator 1 PFIZER INC. $1,856.25 11/20/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832885455
Principal investigator 1 ABBVIE INC. $54.52 11/18/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792483745
Principal investigator 1 Incyte Corporation $702.00 11/18/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145899
Principal investigator 1 Incyte Corporation $4,413.30 11/18/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145905
Principal investigator 1 Incyte Corporation $1,262.00 11/12/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145897
Principal investigator 1 ABBVIE INC. $2,250.00 11/10/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792482359
Principal investigator 1 ABBVIE INC. $4,988.42 11/10/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792482361
Principal investigator 1 Allergan, Inc. $100.00 11/08/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012049
Recipient Eli Lilly and Company $1,678.03 11/08/2021 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819444073
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $550.00 11/04/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 851029541
Principal investigator 1 Incyte Corporation $27,174.17 11/04/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145895
Principal investigator 1 Incyte Corporation $4,314.60 11/04/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145901
Principal investigator 1 Incyte Corporation $81.00 11/04/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145903
Principal investigator 1 Incyte Corporation $4,264.31 11/04/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145907
Principal investigator 1 PFIZER INC. $350.00 11/04/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832877037
Principal investigator 1 PFIZER INC. $1,511.72 11/04/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832917135
Principal investigator 1 Allergan, Inc. $2,000.00 11/01/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012047
Principal investigator 1 Incyte Corporation $786.00 10/25/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145891
Principal investigator 1 ABBVIE INC. $480.49 10/21/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792480175
Principal investigator 1 Incyte Corporation $2,306.00 10/21/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145893
Principal investigator 1 PFIZER INC. $1,686.15 10/21/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832764707
Principal investigator 1 Incyte Corporation $3,446.75 10/15/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145887
Principal investigator 1 Incyte Corporation $1,032.00 10/15/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145889
Principal investigator 1 ABBVIE INC. $230.00 10/14/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792479207
Principal investigator 1 ABBVIE INC. $330.80 10/13/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792478831
Principal investigator 1 Eli Lilly and Company $40,363.97 10/12/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 819450849
Principal investigator 1 PFIZER INC. $1,750.00 10/08/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832877721
Principal investigator 1 ABBVIE INC. $330.80 10/07/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792478441
Principal investigator 1 ABBVIE INC. $1,905.06 10/07/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792478443
Principal investigator 1 Incyte Corporation $2,796.25 10/07/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145885
Principal investigator 1 GW Research Limited $14.90 10/06/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
GWAP19030 No dispute reported 06/30/2026 841422433
Principal investigator 1 Incyte Corporation $11,105.10 10/06/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145879
Principal investigator 1 Incyte Corporation $27,985.50 10/06/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145881
Principal investigator 1 Incyte Corporation $4,290.60 10/06/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145883
Principal investigator 1 ABBVIE INC. $112.50 09/30/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792476853
Principal investigator 1 ABBVIE INC. $185.71 09/29/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792476633
Principal investigator 1 GW Research Limited $2,897.17 09/29/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
GWAP19030 No dispute reported 06/30/2026 841422401
Principal investigator 1 Incyte Corporation $6,532.85 09/24/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145865
Principal investigator 1 PFIZER INC. $2,863.25 09/21/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832728993
Principal investigator 1 Amgen Inc. $49,886.87 09/20/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Interchangeability Study - ABP 654 No dispute reported 06/30/2026 830983039
Principal investigator 1 ABBVIE INC. $187.50 09/16/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792475775
Principal investigator 1 ABBVIE INC. $1,905.06 09/09/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792474857
Principal investigator 1 Incyte Corporation $1,301.00 09/09/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145863
Principal investigator 1 Incyte Corporation $467.00 09/09/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145869
Principal investigator 1 Incyte Corporation $1,567.40 09/09/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145877
Principal investigator 1 Incyte Corporation $3,683.40 09/08/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145875
Principal investigator 1 PFIZER INC. $3,712.50 09/03/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832753761
Principal investigator 1 ABBVIE INC. $545.77 09/02/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792473861
Principal investigator 1 ABBVIE INC. $545.77 09/02/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792473863
Principal investigator 1 Incyte Corporation $18,223.65 09/01/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145861
Principal investigator 1 Incyte Corporation $1,651.86 09/01/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145867
Principal investigator 1 Incyte Corporation $505.00 09/01/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145871
Principal investigator 1 Incyte Corporation $9,309.60 09/01/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145873
Principal investigator 1 Incyte Corporation $973.50 08/20/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145853
Principal investigator 1 Incyte Corporation $3,097.70 08/12/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145851
Principal investigator 1 Incyte Corporation $2,704.31 08/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145835
Principal investigator 1 Incyte Corporation $522.00 08/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145837
Principal investigator 1 Incyte Corporation $10,604.93 08/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145839
Principal investigator 1 Incyte Corporation $50,554.55 08/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145855
Principal investigator 1 Incyte Corporation $1,744.58 08/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145857
Principal investigator 1 Incyte Corporation $11,685.96 08/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145859
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,630.00 08/01/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED DOSE-RANGING TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF INTRAVENOUS MIJ821 INFUSION IN ADDITION TO COMPREHENSIVE STANDARD OF CARE ON THE RAPID REDUCTION OF SYMPTOMS OF MAJOR DEPRESSIVE DISORDER IN SUBJECTS WHO HAVE SUICIDAL IDEATION WITH INTENT No dispute reported 06/30/2026 800640883
Principal investigator 1 ABBVIE INC. $5,541.20 07/29/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792469851
Principal investigator 1 ABBVIE INC. $195.00 07/28/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792468847
Principal investigator 1 ABBVIE INC. $953.88 07/21/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792468251
Principal investigator 1 ABBVIE INC. $1,875.00 07/21/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792468253
Principal investigator 1 ABBVIE INC. $35.43 07/20/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792468109
Principal investigator 1 PFIZER INC. $1,326.78 07/20/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832878389
Principal investigator 1 ABBVIE INC. $1,617.15 07/15/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792467767
Principal investigator 1 Incyte Corporation $2,500.00 07/15/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145823
Principal investigator 1 PFIZER INC. $50.00 07/08/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832834505
Principal investigator 1 PFIZER INC. $1,856.25 07/08/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832870643
Principal investigator 1 ABBVIE INC. $1,905.06 06/30/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792464879
Principal investigator 1 Incyte Corporation $4,016.71 06/30/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145735
Principal investigator 1 Incyte Corporation $12,678.53 06/30/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145737
Principal investigator 1 Incyte Corporation $37,017.68 06/30/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145739
Principal investigator 1 Allergan, Inc. $50.00 06/22/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012045
Principal investigator 1 PFIZER INC. $705.75 06/22/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832698229
Principal investigator 1 PFIZER INC. $5,597.78 06/22/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832805651
Principal investigator 1 GW Research Limited $145.00 06/16/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
GWAP19030 No dispute reported 06/30/2026 841422489
Principal investigator 1 Allergan, Inc. $50.00 06/15/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012043
Principal investigator 1 Incyte Corporation $3,400.00 06/11/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145733
Principal investigator 1 ABBVIE INC. $500.00 06/10/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792462887
Principal investigator 1 ABBVIE INC. $83.26 06/10/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792462889
Principal investigator 1 Allergan, Inc. $50.00 06/09/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012041
Principal investigator 1 GW Research Limited $304.96 06/09/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
GWAP19030 No dispute reported 06/30/2026 841422493
Principal investigator 1 PFIZER INC. $1,896.75 06/04/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832760723
Principal investigator 1 PFIZER INC. $5,265.68 06/04/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832893489
Principal investigator 1 ABBVIE INC. $778.49 06/03/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792462099
Principal investigator 1 ABBVIE INC. $112.50 06/03/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792462101
Principal investigator 1 Incyte Corporation $1,734.35 06/03/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145731
Principal investigator 1 Allergan, Inc. $50.00 06/02/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012039
Principal investigator 1 Incyte Corporation $6,555.44 05/28/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145785
Principal investigator 1 Incyte Corporation $9,652.68 05/28/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145787
Principal investigator 1 Incyte Corporation $36,471.40 05/28/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145789
Principal investigator 1 ABBVIE INC. $3,845.57 05/27/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792460511
Principal investigator 1 Allergan, Inc. $100.00 05/27/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012037
Principal investigator 1 ABBVIE INC. $531.42 05/26/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792459871
Principal investigator 1 PFIZER INC. $11,466.60 05/22/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832764699
Principal investigator 1 PFIZER INC. $1,125.56 05/21/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832839993
Principal investigator 1 ABBVIE INC. $810.00 05/20/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792458701
Principal investigator 1 GW Research Limited $2,897.17 05/19/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
GWAP19030 No dispute reported 06/30/2026 841422491
Principal investigator 1 Avanir Pharmaceuticals, Inc. $6,189.57 05/13/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 807077053
Principal investigator 1 Incyte Corporation $13,941.45 05/11/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145717
Principal investigator 1 Incyte Corporation $2,612.25 05/11/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145719
Principal investigator 1 Incyte Corporation $2,301.85 05/07/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145781
Principal investigator 1 Incyte Corporation $2,965.75 05/07/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145783
Principal investigator 1 PFIZER INC. $2,048.63 05/07/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832801763
Principal investigator 1 PFIZER INC. $873.75 05/07/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832851307
Principal investigator 1 Amgen Inc. $208,276.15 05/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Interchangeability Study - ABP 654 No dispute reported 06/30/2026 830983043
Principal investigator 1 Incyte Corporation $550.00 05/03/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145713
Principal investigator 1 Incyte Corporation $781.25 05/03/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145715
Principal investigator 1 Incyte Corporation $1,768.75 05/03/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145721
Principal investigator 1 Incyte Corporation $9,866.46 04/30/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145805
Principal investigator 1 Incyte Corporation $9,973.13 04/30/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145807
Principal investigator 1 Incyte Corporation $46,532.50 04/30/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145809
Principal investigator 1 Incyte Corporation $8,382.00 04/30/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145813
Principal investigator 1 ABBVIE INC. $1,050.00 04/29/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792449439
Principal investigator 1 ABBVIE INC. $6,786.68 04/29/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792449445
Principal investigator 1 ABBVIE INC. $3,083.36 04/29/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792449451
Principal investigator 1 Incyte Corporation $1,004.50 04/23/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145801
Principal investigator 1 Incyte Corporation $2,380.85 04/23/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145803
Principal investigator 1 Incyte Corporation $1,066.19 04/22/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145709
Principal investigator 1 Incyte Corporation $50.00 04/22/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145711
Principal investigator 1 PFIZER INC. $3,061.13 04/21/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832818449
Principal investigator 1 PFIZER INC. $4,782.50 04/21/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832858573
Principal investigator 1 Incyte Corporation $488.45 04/16/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145799
Principal investigator 1 Allergan, Inc. $4,571.40 04/14/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012035
Principal investigator 1 ABBVIE INC. $120.00 04/13/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792444783
Principal investigator 1 Amgen Inc. $1,017.16 04/12/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Interchangeability Study - ABP 654 No dispute reported 06/30/2026 830983041
Principal investigator 1 Incyte Corporation $114.75 04/09/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145797
Principal investigator 1 ABBVIE INC. $300.00 04/08/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792443285
Principal investigator 1 ABBVIE INC. $500.00 04/08/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792443289
Principal investigator 1 PFIZER INC. $3,281.06 04/08/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832793467
Principal investigator 1 PFIZER INC. $3,196.13 04/08/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832797745
Principal investigator 1 ABBVIE INC. $83.07 04/06/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792442731
Principal investigator 1 Incyte Corporation $12,883.00 04/02/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145793
Principal investigator 1 Incyte Corporation $3,168.80 04/02/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145795
Principal investigator 1 ABBVIE INC. $2,000.00 04/01/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792440795
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 04/01/2021 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806247197
Principal investigator 1 ABBVIE INC. $1,322.18 03/30/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792437479
Principal investigator 1 Incyte Corporation $14,571.80 03/26/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145771
Principal investigator 1 Incyte Corporation $4,652.79 03/26/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145773
Principal investigator 1 Incyte Corporation $40,491.23 03/26/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145775
Principal investigator 1 Allergan, Inc. $500.00 03/24/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012033
Principal investigator 1 Eli Lilly and Company $69,120.33 03/24/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A PHASE 3, 16-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL- GROUP STUDY TO ASSESS THE IMPACT OF LEBRIKIZUMAB ON VACCINE RESPONSES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 819449967
Principal investigator 1 PFIZER INC. $12,296.67 03/23/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832834495
Principal investigator 1 PFIZER INC. $5,211.13 03/23/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832903347
Principal investigator 1 Incyte Corporation $225.00 03/19/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145769
Principal investigator 1 Incyte Corporation $225.00 03/19/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145777
Principal investigator 1 ABBVIE INC. $270.92 03/18/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792434207
Principal investigator 1 Avanir Pharmaceuticals, Inc. $2,631.65 03/18/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
17-AVP-786-305 No dispute reported 06/30/2026 807074383
Principal investigator 1 Avanir Pharmaceuticals, Inc. $5,657.00 03/18/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
17-AVP-786-305 No dispute reported 06/30/2026 807074393
Principal investigator 1 Incyte Corporation $1,343.26 03/18/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145707
Principal investigator 1 ABBVIE INC. $256.35 03/17/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792433823
Principal investigator 1 ABBVIE INC. $75.00 03/17/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792433827
Principal investigator 1 Allergan, Inc. $4,571.40 03/17/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012031
Principal investigator 1 ABBVIE INC. $243.75 03/12/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792433455
Principal investigator 1 Incyte Corporation $395.00 03/12/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145765
Principal investigator 1 Incyte Corporation $2,458.82 03/12/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145767
Principal investigator 1 ABBVIE INC. $4,686.33 03/09/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792432753
Principal investigator 1 ABBVIE INC. $1,350.00 03/08/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792432511
Principal investigator 1 Incyte Corporation $231.00 03/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145763
Principal investigator 1 PFIZER INC. $2,300.00 03/05/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832778005
Principal investigator 1 PFIZER INC. $1,928.25 03/05/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832810361
Principal investigator 1 ABBVIE INC. $4,887.42 03/02/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792428539
Principal investigator 1 Incyte Corporation $16,900.99 02/26/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145755
Principal investigator 1 Incyte Corporation $1,819.80 02/26/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145757
Principal investigator 1 Incyte Corporation $46,660.74 02/26/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145759
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $747.90 02/24/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (TRIAL 405-201-00014) No dispute reported 06/30/2026 844173403
Principal investigator 1 PFIZER INC. $8,490.29 02/23/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832724659
Principal investigator 1 Incyte Corporation $4,754.73 02/19/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145753
Principal investigator 1 Incyte Corporation $1,990.58 02/17/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145703
Principal investigator 1 Incyte Corporation $3,573.46 02/17/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145705
Principal investigator 1 ABBVIE INC. $1,719.77 02/15/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792423259
Principal investigator 1 ABBVIE INC. $75.00 02/15/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792423265
Principal investigator 1 Incyte Corporation $150.00 02/12/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145749
Principal investigator 1 Incyte Corporation $100.00 02/12/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145751
Principal investigator 1 Avanir Pharmaceuticals, Inc. $4,637.95 02/11/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 807074263
Principal investigator 1 Incyte Corporation $100.00 02/11/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145701
Principal investigator 1 GW Research Limited $2,897.17 02/10/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
GWAP19030 No dispute reported 06/30/2026 841422555
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,171.36 02/09/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICAL RESEARCH
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 800619151
Principal investigator 1 Incyte Corporation $147.15 02/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145745
Principal investigator 1 Incyte Corporation $11,848.09 02/05/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145747
Principal investigator 1 Incyte Corporation $2,000.00 02/04/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145697
Principal investigator 1 Incyte Corporation $5,400.00 02/04/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145699
Principal investigator 1 PFIZER INC. $11,690.40 02/04/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832835497
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,023.74 02/04/2021 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806247153
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $5,125.00 02/03/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE AS ADJUNCTIVE THERAPY IN THE MAINTENANCE TREATMENT OF ADULTS WITH MAJOR DEPRESSIVE DISORDER. No dispute reported 06/30/2026 844172429
Principal investigator 1 Allergan, Inc. $850.00 02/02/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012029
Principal investigator 1 Allergan, Inc. $225.00 02/01/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012027
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,626.28 02/01/2021 Non-covered Recipient Entity
Olympian Clinical Research - South Tampa Office
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 819898609
Principal investigator 1 Incyte Corporation $65,333.93 01/29/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 831145815
Principal investigator 1 Incyte Corporation $3,639.60 01/29/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo No dispute reported 06/30/2026 831145817
Principal investigator 1 Incyte Corporation $9,676.64 01/29/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 831145819
Principal investigator 1 ABBVIE INC. $1,905.06 01/28/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 792414949
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $175.00 01/27/2021 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806247159
Principal investigator 1 Incyte Corporation $400.00 01/26/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145691
Principal investigator 1 Incyte Corporation $131.25 01/26/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145693
Principal investigator 1 Allergan, Inc. $6,098.05 01/22/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICA
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 789012025
Principal investigator 1 Avanir Pharmaceuticals, Inc. $125.00 01/21/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
15-AVP-786-303 No dispute reported 06/30/2026 807074319
Principal investigator 1 Novartis Pharmaceuticals Corporation $140,769.42 01/19/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY OLYMPIAN CLINICAL RESEARCH
A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNRISE No dispute reported 06/30/2026 800619161
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $14,021.93 01/13/2021 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
AN OPEN-LABEL, 52-WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 844171331
Principal investigator 1 Incyte Corporation $100.00 01/12/2021 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 831145695
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,952.20 01/11/2021 Non-covered Recipient Entity
Olympian Clinical Research - South Tampa Office
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 819898603
Principal investigator 1 Biogen, Inc. $48,528.27 01/08/2021 Non-covered Recipient Entity
Academic Alliance In Dermatology
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease No dispute reported 06/30/2026 829000069
Principal investigator 1 PFIZER INC. $8,660.25 01/08/2021 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832816085
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 01/08/2021 Non-covered Recipient Entity
ACADEMIC ALLICANCE IN DERMATOLOGY INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 806247155